Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 2 study to evaluate the safety and efficay of AT-101 in
combination with rituximab in patients with relapsed or refractory chronic lymphocytic
leukemia.